SALT LAKE CITY, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced an agreement with Hannah Storm, a nationally ...

Myriad Genetics enters into an agreement with Hannah Storm, who will be the Myriad Genetics Breast Cancer Risk Assessment Program ambassador.

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced a study revealing that more patients completed hereditary cancer testing when they used an online ...

Myriad Genetics partners with broadcaster Hannah ... Storm will promote the MyRisk® with RiskScore® Hereditary Cancer Test, which evaluates genetic risks for various cancers.

Under the agreement, Storm will act as an ambassador for the Myriad Genetics Breast Cancer Risk Assessment Program, which features the MyRisk with RiskScore Hereditary Cancer test. The latest ...

Myriad Genetics faces a tough year ahead with new policy changes. Learn why MYGN stock has cratered and if it's poised for ...

Myriad Genetics (NASDAQ:MYGN – Get Free Report) was upgraded by stock analysts at StockNews.com from a “hold” rating to a ...

MyRisk with RiskScore provides eligible patients with a five-year and remaining lifetime breast cancer risk assessment individualized to them. Myriad Genetics is a leading genetic testing and ...

Under the agreement, Storm will act as an ambassador for the Myriad Genetics Breast Cancer Risk Assessment Program featuring the MyRisk® with RiskScore® Hereditary Cancer Test, the first and ...